Dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

ABSTRACT:

Background

Dabrafenib plus trametinib improves clinical outcomes in BRAF^V600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAF^V600-mutant melanoma brain metastases.

Methods

This ongoing, multicentre, multicohort, open-label, phase 2 study evaluated oral dabrafenib (150 mg twice per day) plus oral trametinib (2 mg once per day) in four patient cohorts with melanoma brain metastases enrolled from 32 hospitals and in

SUBMITTER: Davies MA 

PROVIDER: S-EPMC5991615 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature